{"filing":{"accession_number":"0001193125-26-234858","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"d139014d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/d139014d8k.htm"},"events":[{"id":9434,"run_id":8273,"accession_number":"0001193125-26-234858","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The Company disclosed receipt of a Nasdaq notice on March 17, 2026 that it had failed to maintain the minimum market value of listed securities ($50 million) required under Nasdaq Listing Rule 5450(b)(2)(A). Although the Company subsequently regained compliance by May 20, 2026 based on stockholders' equity meeting Rule 5450(b)(1)(A), the disclosure centers on a delisting risk event—the failure to satisfy a continued listing rule and the subsequent resolution. This is material to investors as it directly affects the Company's ability to remain listed on Nasdaq.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-05-21","submitted_at":null,"items":[{"id":1076,"accession_number":"0001193125-26-234858","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Company disclosed receipt of a Nasdaq notice on March 17, 2026 that it had failed to maintain the minimum market value of listed securities ($50 million) required under Nasdaq Listing Rule 5450(b)(2)(A). Although the Company subsequently regained compliance by May 20, 2026 based on stockholders' equity meeting Rule 5450(b)(1)(A), the disclosure centers on a delisting risk event—the failure to satisfy a continued listing rule and the subsequent resolution. This is material to investors as it directly affects the Company's ability to remain listed on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:15.064921+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1076,"accession_number":"0001193125-26-234858","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Company disclosed receipt of a Nasdaq notice on March 17, 2026 that it had failed to maintain the minimum market value of listed securities ($50 million) required under Nasdaq Listing Rule 5450(b)(2)(A). Although the Company subsequently regained compliance by May 20, 2026 based on stockholders' equity meeting Rule 5450(b)(1)(A), the disclosure centers on a delisting risk event—the failure to satisfy a continued listing rule and the subsequent resolution. This is material to investors as it directly affects the Company's ability to remain listed on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:15.064921+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-05-21"}]}